Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


27.08.2018

1 Acta Neurol Scand
4 BMC Neurol
1 Clin Exp Immunol
1 Lancet Neurol
2 Mult Scler
1 Neurology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Neurol Scand

  1. HAGHIGHI S, Forsmark S, Carlsson A, Nilsson MKL, et al
    Open study with (-)-OSU6162 in multiple sclerosis-related fatigue.
    Acta Neurol Scand. 2018 Aug 22. doi: 10.1111/ane.13007.
    PubMed     Text format     Abstract available


    BMC Neurol

  2. KOTTERBA S, Neusser T, Norenberg C, Bussfeld P, et al
    Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study.
    BMC Neurol. 2018;18:123.
    PubMed     Text format     Abstract available

  3. TRABOULSEE A, Li DKB, Cascione M, Fang J, et al
    Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
    BMC Neurol. 2018;18:68.
    PubMed     Text format     Abstract available

  4. FRAU J, Fenu G, Signori A, Coghe G, et al
    A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls.
    BMC Neurol. 2018;18:67.
    PubMed     Text format     Abstract available

  5. SUNTER G, Enver EO, Akbarzade A, Turan S, et al
    Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency.
    BMC Neurol. 2018;18:48.
    PubMed     Text format     Abstract available


    Clin Exp Immunol

  6. LI Z, Richards S, Surks HK, Jacobs A, et al
    Clinical Pharmacology of Alemtuzumab, an Anti-CD52 Immunomodulator, in Multiple Sclerosis.
    Clin Exp Immunol. 2018 Aug 24. doi: 10.1111/cei.13208.
    PubMed     Text format     Abstract available


    Lancet Neurol

  7. TRAPP BD, Vignos M, Dudman J, Chang A, et al
    Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.
    Lancet Neurol. 2018 Aug 21. pii: S1474-4422(18)30245.
    PubMed     Text format     Abstract available


    Mult Scler

  8. BOVE R, Bevan C, Crabtree E, Zhao C, et al
    Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
    Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
    PubMed     Text format     Abstract available

  9. NICHOLAS RS, Han E, Raffel J, Chataway J, et al
    Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
    Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
    PubMed     Text format     Abstract available


    Neurology

  10. MIDAGLIA L, Gratacos M, Caronna E, Raguer N, et al
    Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
    Neurology. 2018 Aug 24. pii: WNL.0000000000006251.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: